Mast Therapeutics (MSTX) is up 12% in early action.
The company says MST-188 "demonstrated a statistically significant improvement in numerous parameters of heart function," in a nonclinical heart failure model.
The data collected suggest the treatment may be promising way to improve left ventricular ejection fraction and end-systolic volume.
The company intends to "provide an update on its plans for MST-188 in heart failure later in 2014." (PR)